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ABSTRACT 61 
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder whose symptoms 62 
include abdominal pain associated with a change in stool form or frequency. The condition 63 
affects between 5% and 10% of otherwise healthy individuals in the community at any one 64 
point in time and, in most people, runs a relapsing and remitting course. The best described 65 
risk factor is acute enteric infection, but IBS is also more common in people with 66 
psychological co-morbidity, and in young adult females. The pathophysiology of IBS 67 
remains incompletely understood, but it is well established that there is disordered 68 
communication between the gut and the brain, leading to motility disturbances, visceral 69 
hypersensitivity, and altered central nervous system processing. Other less reproducible 70 
mechanisms may include genetic associations, alterations in gastrointestinal microbiota, and 71 
disturbances in mucosal and immune function. In most people the diagnosis can be made 72 
based on the clinical history, with limited, judicious, use of investigations, unless alarm 73 
symptoms such as weight loss or rectal bleeding are present, or there is a family history of 74 
inflammatory bowel disease or coeliac disease. Once the diagnosis is made, an empathetic 75 
approach is key, and can improve quality of life and symptoms, and reduce health care 76 
expenditure. The mainstays of treatment include patient education about the condition, 77 
dietary changes, soluble fibre, and antispasmodic drugs. Other treatments tend to be reserved 78 
for those with more severe symptoms; these include central neuromodulators, intestinal 79 
secretagogues, drugs acting on 5-hydroxytryptamine or opioid receptors, or minimally 80 
absorbed antibiotics (all of which are selected according to predominant bowel habit), and 81 
psychological therapies. The increased understanding of the pathophysiology of IBS in the 82 
last 10 years has led to a healthy pipeline of novel drugs in development.  83 
  84 
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INTRODUCTION 85 
 Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that has a 86 
substantial impact on quality of life and social functioning. 1,2 The pathophysiology of IBS is 87 
only partially understood. 3 It affects between and 5% and 10% of the general population, 4 88 
and is characterised by recurrent abdominal pain in association with abnormal stool form or 89 
frequency. 5 Treatment aims to improve both abdominal pain and bowel habit, but often is 90 
targeted towards the most troublesome symptom. First-line therapies include dietary changes, 91 
soluble fibre, and antispasmodic drugs; in patients with more severe symptoms, treatments 92 
include central neuromodulators, including low-dose tricyclic antidepressants (TCAs), 93 
intestinal secretagogues, drugs acting on opioid or 5-hydroxytryptamine (5-HT) receptors, 94 
antibiotics, and psychological therapies. 6 The annual direct and indirect costs related to IBS 95 
are estimated to be up to €8 billion in Europe, 7 ¥123 billion in China, 8 and in excess of $10 96 
billion in the USA. 9 97 
 98 
SEARCH STRATEGY AND SELECTION CRITERIA 99 
We searched the medical literature using MEDLINE, EMBASE, EMBASE Classic, 100 
and the Cochrane central register of controlled trials during the last 10 years with the terms 101 
“irritable bowel syndrome”, “epidemiology”, “prevalence”, “incidence”, “aetiology”, 102 
“pathophysiology”, “diagnosis”, “investigation”, “management”, “therapy”, and “treatment” 103 
in order to identify pertinent articles. In addition, we searched clinicaltrials.gov for 104 
unpublished trials. We included only publications in English, and selected those articles 105 
whose findings were, in our view, of the greatest importance, favouring randomised 106 
controlled trials, meta-analyses, and network meta-analyses. 107 
 108 
 109 
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EPIDEMIOLOGY 110 
 The most recent symptom-based diagnostic criteria for IBS, the Rome IV criteria, 111 
were developed by consensus among experts in functional gastrointestinal disorders. The 112 
criteria consist of abdominal pain associated with an alteration in either stool form or 113 
frequency, occurring for at least 6 months. 5 Patients are subgrouped according to 114 
predominant stool pattern, using the Bristol stool form scale: 10 IBS with diarrhoea (IBS-D), 115 
IBS with constipation (IBS-C), IBS with mixed stool pattern (IBS-M), and IBS unclassified 116 
(IBS-U) (Table 1). Methodological limitations make it difficult to obtain reliable estimates of 117 
prevalence, 11 particularly because, in the absence of universally accepted biomarkers of 118 
disease, the diagnosis relies on self-reported symptom clusters. However, as organic 119 
gastrointestinal disease in the community is relatively rare, and a diagnosis of IBS is made 120 
based on the presence of typical symptoms, population-based epidemiological studies provide 121 
a close approximation of true prevalence, which is between 5% and 10% in most 122 
geographical regions (Figure 1). 4 123 
 Various iterations of these symptom-based diagnostic criteria have resulted in 124 
differences in reported prevalence, but disease impact is substantial even in people felt to 125 
have IBS, but not meeting such criteria. 12 In addition, both symptom interpretation and 126 
reporting are influenced by cultural factors, and can vary among ethnic groups.11 Prior to 127 
publication of the Rome IV criteria in 2016, 5 two systematic reviews examining global 128 
prevalence of IBS were conducted. 4,13 The first reported a pooled prevalence of 11.2% (95% 129 
confidence interval (CI) 9.8% to 12.8%), 13 ranging from 1.1% in Iran, using the Rome III 130 
criteria, to 45% in Pakistan using Rome II. The second review reported a global prevalence of 131 
8.8% (95% CI 8.7% to 8.9%). 4 Prevalence varied widely, from 1.1% in France using the 132 
Rome II criteria, and Iran using Rome III, to 35.5% in Mexico using Rome II. 14 Thus, 133 
Ford et al.  Page 7 of 54 
 
despite commonly accepted prevalence ranges, variation in estimates between studies is 134 
large, partly due to methodological heterogeneity.  135 
 Findings from a Rome Foundation 33-nation cross-sectional survey, examining 136 
worldwide prevalence and burden of functional gastrointestinal disorders in over 73,000 137 
individuals in 26 countries, were published in 2020. 15 Using Rome IV criteria, prevalence 138 
rates ranged between 2% and 6%, with a pooled prevalence of 4.1%. In countries where both 139 
Rome III and IV criteria were applied, pooled prevalence fell from 10.1% with Rome III to 140 
3.8% for Rome IV. However, there remains a dearth of prevalence data from Africa, Eastern 141 
Europe, and the Middle East.  142 
 143 
RISK FACTORS 144 
 In two systematic reviews, rates of IBS were significantly higher in females 4,13 and, 145 
when 14 studies were pooled, prevalence was lower in those aged ≥50 (odds ratio (OR) 0.75; 146 
95% CI 0.62 to 0.92) compared with those aged <50 years. 13 There are no reliable data on 147 
IBS and socio-economic status. IBS is more common in patients with functional somatic 148 
syndromes, such as fibromyalgia and chronic fatigue. 16 Many other psychosocial, biological, 149 
and environmental factors are associated with IBS, and may influence symptom severity 150 
(Figure 2). However, it is unclear if these are genuine risk factors; most studies are cross-151 
sectional, and lack the temporal element needed to determine cause and effect.  152 
 Perhaps the best-recognised risk factor for IBS, observed in approximately 10% of 153 
patients, 17 is prior acute enteric infection. This is termed post-infection IBS (PI-IBS), and 154 
can occur after bacterial, viral, or protozoal infection. 18 In one retrospective cohort study, 155 
even non-specific gastrointestinal infections, which comprised the vast majority of cases, 156 
were associated with an equally high risk of PI-IBS to culture-confirmed bacterial or viral 157 
infections. 19 A meta-analysis of 45 observational studies reported a four-fold increase in 158 
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odds of developing IBS in exposed individuals 12 months post-infection (OR 4.2; 95% CI 3.1 159 
to 5.7). 18 Risk factors for development of PI-IBS included female sex, antibiotic exposure, 160 
psychological distress preceding the illness, and severity of infection. 18 Prognosis may be 161 
better than in those with a non-infectious cause although, in one longitudinal follow-up study, 162 
15% of those with PI-IBS remained symptomatic 8 years later. 20  163 
 164 
PATHOPHYSIOLOGY 165 
 The biopsychosocial model to explain symptoms of abdominal pain and disordered 166 
bowel habit in IBS conceptualised a genetic predisposition, where adverse events in early 167 
life, psychological factors, or gastrointestinal infections then trigger alterations in the enteric 168 
nervous system, which controls gastrointestinal motor, sensory, mucosal barrier, and 169 
secretory responses (Figure 3). 21  170 
 171 
“Traditional” Mechanisms: The Brain-gut Axis, Stress, Visceral Hypersensitivity, and 172 
Altered Motility 173 
 In addition to the psychological component of IBS, 22 gut-brain communication is 174 
bidirectional. Prospective longitudinal studies demonstrate that a subset of patients 175 
experience gastrointestinal symptoms first, 23,24 and psychological distress later. 176 
Gastrointestinal infection and psychological disorders appear to be distinct risk factors, 177 
contributing additively to the development of both PI-IBS and the extra-intestinal symptoms 178 
frequently linked to IBS, such as chronic fatigue. 19 179 
 Altered visceral sensation in IBS is characterised by central abnormalities in sensory, 180 
emotional arousal, and prefrontal cortical regions of the brain. Alterations in the descending 181 
pathways modulating sensation, and peripheral mechanisms are also involved in the 182 
pathogenesis of visceral pain. 25 On average, about 60% of patients exhibit increased 183 
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sensitivity of the gut to different physiological stimuli. 26,27 Disordered motility in IBS is 184 
manifested by abnormal colonic myoelectric activity, 28 repetitive contractions of the small 185 
intestine and colon, associated with abdominal pain, and alterations in gastrointestinal or 186 
colonic transit. 29,30 Accumulation of different mechanisms (psychological, sensory, and 187 
motor) increases both gastrointestinal and non-gastrointestinal symptom severity, as well as 188 
impairments in quality of life. 31,32 189 
 190 
The Gut Microenvironment 191 
 As many IBS patients report that their symptoms are associated with eating, or 192 
eliminating, certain foods, 33 it has been assumed that diet and, more recently, gastrointestinal 193 
microbiota are involved in pathophysiology.  194 
 195 
Dietary FODMAPs and Disaccharide Maldigestion  196 
Fermentable oligo-, di-, and mono-saccharides and polyols (FODMAPs) are present 197 
in high levels in some fruits, artificial sweeteners, legumes, and green vegetables, and are 198 
poorly absorbed in all individuals. They have fermentative and osmotic effects, which may 199 
contribute to symptoms in some patients. 34 Although randomised controlled trials (RCTs) 200 
have confirmed that dietary modification can affect IBS symptoms, so far, they have not 201 
confirmed symptom generation by a specific food. Patients with IBS exhibit comparable 202 
increases in small intestinal water content and colonic volume to FODMAPs to those seen in 203 
healthy individuals, but symptomatic responses are greater in IBS, supporting the role of 204 
visceral hypersensitivity. 35 Dietary disaccharide maldigestion may induce symptoms 205 
secondary to osmotic diarrhoea and gas production following fermentation of unabsorbed 206 
sugars, 36,37 due to disaccharidase deficiency, classically lactase or, as more recently 207 
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demonstrated in 4% of patients with IBS, 38,39 sucrase-isomaltase, which digests sucrose and 208 
starch.  209 
 210 
The Microbiome 211 
 Although some studies demonstrate that patients with IBS have a different 212 
gastrointestinal microbiome, compared with healthy controls, 40,41 the role of the microbiota 213 
is still questioned, particularly because what constitutes a “healthy” microbiome remains 214 
unclear. A systematic review demonstrated few consistent findings in IBS (possibly because 215 
age, sex, race, diet, and antibiotic intake were not controlled for in included studies), and 216 
certainly no microbiome signature differentiating IBS subgroups. 42 Antibiotics change the 217 
intestinal microbiome, and have been associated with development of IBS. 43 Small intestinal 218 
bacterial overgrowth (SIBO), has also been implicated, 44 but its role is controversial due, in 219 
large part, to limitations of available diagnostic tests, such as glucose and lactulose breath 220 
tests 45 and culture of jejunal aspirates. 46 221 
 222 
Bile Acids 223 
 Up to 25% of patients who meet criteria for IBS-D have idiopathic bile acid 224 
diarrhoea, demonstrated by abnormal retention following 23-seleno-25-homotaurocholic acid 225 
(SeHCAT) scanning, 47 or total 48-hour faecal bile acid levels. 48 The latter correlated with 226 
stool number and form, and colonic transit, in one case series of patients. 49 Excess faecal bile 227 
acids in IBS-D appeared to be associated with dysbiosis, specifically a Clostridia-rich 228 
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Barrier Function and Immune Activation  233 
Acute gastrointestinal infections induce changes in intestinal permeability and the 234 
microbiome. 51 This may promote activation of immune cells, including T-lymphocytes and 235 
mast cells, in the gastrointestinal epithelium, 52 leading to cytokine release, which can modify 236 
neural control of gastrointestinal motor, sensory, and secretory functions. Pathophysiological 237 
alterations can last for years. For example, in PI-IBS neuronal signalling remained sensitised 238 
2 years after the infection. 53 Other investigators have reported increased gastrointestinal 239 
permeability and elevated immune cell counts, even in patients with IBS without an infective 240 
aetiology. 54,55  241 
 242 
Genetics 243 
 Although research into the genetics of IBS lags behind other conditions, like 244 
inflammatory bowel disease (IBD), genome-wide association studies have provided 245 
associations with variants on chromosome 9 (9q31.2 locus) that are linked to the functions of 246 
diverse ion channels and autonomic dysfunction, 56 and mutations in the sucrase-isomaltase 247 
gene, 38,39 as previously discussed. In addition, approximately 2% of IBS patients carry 248 
missense mutations in SCN5A, 57 which alters the function of the voltage-gated 249 
mechanosensitive Na+ channel Nav1.5, and affects smooth muscle function and mechanical 250 
sensitivity. In twin studies, concordance of a diagnosis of IBS is commoner in monozygotic, 251 
compared with dizygotic twins; however, having a parent with IBS is a stronger predictor, 252 
suggesting that environmental factors such as learned illness behaviour are more important. 58  253 
 254 
CLINICAL PRESENTATION AND DIFFERENTIAL DIAGNOSIS 255 
 Although IBS is a multifactorial and heterogeneous disorder, there are some typical 256 
features. The condition is most common among females aged 20 to 40 years, 4,13 although in 257 
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some countries appears more prevalent in males. 59 It can occur at any age; 15 the average age 258 
of participants in clinical trials of novel drugs in IBS is around 45 years, illustrating the broad 259 
age range of patients. Coexistent mood problems and extra-intestinal symptoms, including 260 
back pain, gynaecological and bladder symptoms, headache, and fatigue are common, 60,61 as 261 
is overlap with other functional gastrointestinal disorders. 62 The presence of abdominal pain 262 
is essential to the definition of IBS. Accordingly, the differential diagnosis is broad, but other 263 
features help narrow this down. Firstly, as IBS is a chronic disorder, causes of acute 264 
abdominal pain are ruled out. Secondly, the pain is recurrent, but it is intermittent rather than 265 
continuous. Thirdly, pain is usually in the lower abdomen, although Asian patients may 266 
report upper abdominal pain. 63 Finally, and most critically, pain in IBS is associated with 267 
defaecation, and occurs at the time when the patient experiences alterations in stool frequency 268 
or consistency. 5 Although IBS is subgrouped according to predominant stool pattern, 5 this 269 
fluctuates in many patients. 64 Abdominal bloating is not a cardinal symptom but is very 270 
common, and supports the diagnosis, particularly if it is diurnal. It is often accompanied by 271 
visible abdominal distension. 65 272 
 In order to understand the precise meaning of terms such as diarrhoea or constipation, 273 
as well as the impact of the disorder on social functioning and wellbeing, a thorough history 274 
is essential. The Bristol stool form scale is a useful tool to assess stool consistency in the 275 
clinic, and can be used to direct treatment, which is discussed later. A detailed history helps 276 
differentiate between IBS and other disorders characterised by abdominal pain in association 277 
with altered bowel habit, including coeliac disease, IBD, colorectal cancer (CRC), and 278 
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INVESTIGATIONS 283 
 Although there is no universally accepted biomarker for IBS, exhaustive investigation 284 
to exclude an organic cause for the symptoms is discouraged, as this is expensive, and many 285 
patients are not reassured by such an approach. 66 Once a clinical diagnosis of IBS is made, it 286 
is unlikely to be revised, even during extended follow-up. 67 Guidelines recommend a 287 
“positive” diagnosis using symptom-based diagnostic criteria, such as the Rome criteria, and 288 
minimising investigations (Figure 4). 6 Although the Rome IV criteria have yet to be 289 
validated independently, in secondary care sensitivity of the Rome III criteria was 68.8%, 290 
specificity 79.5%, and positive and negative likelihood ratios 3.35 and 0.39, respectively. 68 291 
The addition of other features from the clinical history, including absence of nocturnal stools, 292 
presence of anxiety, depression, or extra-intestinal symptoms, and a normal full blood count 293 
and C-reactive protein enhances the diagnostic performance of the Rome III criteria. 69  294 
 There is little evidence to support a routine panel of blood tests, other than full blood 295 
count, C-reactive protein, and serological screening for coeliac disease, which has a 296 
prevalence of 1% in most Western countries, and is an important differential diagnosis. A 297 
meta-analysis demonstrated an almost three-fold higher odds of positive coeliac serology in 298 
patients with symptoms suggestive of IBS (OR 2.75; 95% CI 1.35 to 5.61), compared with 299 
healthy controls, irrespective of predominant stool pattern. 70  300 
 Whether any further investigations are required in a patient with new onset symptoms 301 
depends, to some extent, on bowel habit, unless alarm symptoms or signs (Table 2) are 302 
present. 71 The latter are an indication for urgent colonoscopy. Colonoscopy should also be 303 
performed if the patient is aged ≥50 years and has not already had age-related CRC 304 
screening. In addition, unexplained rectal bleeding or iron-deficiency anaemia needs 305 
investigation, regardless of age. A family history of coeliac disease, IBD, or CRC is also 306 
relevant. In a patient with IBS-C, the diagnosis is secure, unless there are obstructive 307 
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symptoms (excessive straining, sense of incomplete rectal evacuation, or digitation of the 308 
anus to facilitate defaecation) or digital rectal examination suggests a defaecatory disorder, 72 309 
which is the result of incoordination of the normal functions required for rectal evacuation. If 310 
present, anorectal manometry with balloon expulsion testing may be helpful, as the treatment 311 
of choice for these conditions is biofeedback, 73 rather than dietary or drug therapy.  312 
 In a patient with diarrhoea, there may be greater concern for a missed organic 313 
diagnosis. Faecal calprotectin, which is a cytosol protein released by neutrophils, can 314 
differentiate between IBS and IBD, 74,75 avoiding the need for colonoscopy, for which the 315 
yield is low. In a cross-sectional survey of almost 500 patients with IBS, only 0.4% of 316 
patients were found to have IBD at colonoscopy, 1.5% MC, and there were no cases of CRC. 317 
76 MC is more common in females over the age of 45 years. There are other clues to MC as a 318 
cause of symptoms, rather than IBS, which should lead to consideration of colonoscopy to 319 
obtain colonic biopsies. These include the fact that the presence of abdominal pain is 320 
variable, duration of symptoms tends to be shorter, and patients often have coexistent 321 
autoimmune disease, report nocturnal diarrhoea and weight loss, or are taking drugs, such as 322 
a non-steroidal anti-inflammatory drug or a proton pump inhibitor. 77,78  323 
 Bile acid diarrhoea is another important differential in patients presenting with IBS-D, 324 
as its estimated population prevalence is 1%. It can be diagnosed using SeHCAT scanning, a 325 
fasting serum 7α-hydroxy-4-cholesten-3-one, fibroblast growth factor-19, or 48-hour faecal 326 
bile acid excretion, 79 but these are not universally available. A therapeutic trial of a bile acid 327 
sequestrant as a surrogate diagnostic test is an alternative, although it is unclear what dose 328 
should be used, and problems with medication compliance may compromise its utility. 80  329 
The reported association between SIBO and IBS is contentious. 44 Investigations to 330 
exclude SIBO should only be considered in patients with clear risk factors, such as previous 331 
gastric or intestinal surgery, or known structural abnormalities, including jejunal 332 
Ford et al.  Page 15 of 54 
 
diverticulosis. Hydrogen breath tests may be falsely positive, as they are a marker for rapid 333 
transit. 45 Instead, culture of jejunal aspirates should be considered if SIBO is suspected. 81 334 
 335 
NATURAL HISTORY AND IMPACT 336 
 The typical course in IBS consists of fluctuating symptoms, in terms of bowel habit. 64 337 
Incidence of new-onset IBS was approximately 1.5% to 2.5% per year, over 10 to 12 years, in 338 
three longitudinal studies. 82-84 However, prevalence remains stable, because the number of 339 
people developing new symptoms is matched by the number whose symptoms disappear or 340 
fluctuate to another functional gastrointestinal disorder. 83,84 IBS causes morbidity, but not 341 
mortality, 85 and affects quality of life 1 to the same degree as organic gastrointestinal 342 
disorders such as Crohn’s disease. 86  343 
 It also impacts work productivity, 1,2 social integration, and psychosocial factors, such 344 
as general and gut-related anxiety, depression, and somatisation. 60,87 Some of these 345 
associations are bidirectional, 23,24 so that psychosocial factors can exacerbate IBS symptoms, 346 
and the illness experience, and vice versa. One cross-sectional survey showed the impact on 347 
daily activity differs according to stool pattern; those with IBS-D avoided travel or leaving 348 
the house, due to concerns about toilet access, and those with IBS-C avoided sexual 349 
intercourse and reported difficulty concentrating. 88 Associations with severity include 350 
overlap with other functional gastrointestinal disorders, 62 and consulter status. 89 However, 351 
those who consult with symptoms also have poorer quality of life, increased rates of 352 
psychological symptoms, and reduced coping. 89 There is a direct correlation between number 353 
of overlapping functional gastrointestinal disorders, reduced quality of life, and increased 354 
health care utilisation and gastrointestinal surgery. 62 Patients are willing to accept a 1% 355 
median risk of sudden death in return for a 99% chance of cure of their symptoms with a 356 
hypothetical medication. 90 357 
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MANAGEMENT 358 
 As no medical therapy is proven to alter the natural history of IBS, and the majority of 359 
RCTs are only conducted over a 12-week period meaning that their long-term efficacy is 360 
unknown, an empathetic approach is key. This can improve quality of life and symptoms, 91 361 
reduce health care visits, and enhance adherence to treatment. 92,93 Management should 362 
commence with explanation of the disorder, its pathophysiology, and natural history. In fact, 363 
structured patient education about the condition led to a significantly greater improvement in 364 
symptoms, compared with written information, in one RCT. 94 Treatment is directed towards 365 
the predominant symptom, with a realistic discussion of the limitations of available therapies, 366 
in order to manage expectations, as most improve symptoms in only 25% to 30% of patients 367 
(Table 3), and have only been tested in referral populations. The final decision as to the 368 
choice of treatment should be the patient’s, after they receive full information on available 369 
options in a dialogue with the doctor. 370 
 371 
Lifestyle, Diet, and Probiotics 372 
 The effect of lifestyle changes in IBS has not been well studied; in a small RCT of 373 
physiotherapist-administered exercise, symptoms improved significantly, compared with a 374 
control arm with no changes to physical activity. 95 Traditionally, patients with IBS were told 375 
to increase dietary fibre intake. However, bran may exacerbate symptoms, 96 although 376 
ispaghula husk was more efficacious than placebo in a meta-analysis of seven RCTs (relative 377 
risk (RR) of remaining symptomatic 0.83; 95% CI 0.73 to 0.94). 97 Several RCTs 378 
demonstrate that FODMAP restriction leads to an improvement in IBS symptoms, compared 379 
with habitual diet. 98,99 However, other RCTs suggest that “traditional” dietary advice to eat 380 
small regular meals, avoid known trigger foods, and reduce alcohol and caffeine, is as 381 
effective as a low FODMAP diet. 100,101 Long-term FODMAP restriction may lead to 382 
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deleterious alterations in the microbiome. 102 FODMAPs should, therefore, be reintroduced to 383 
tolerance after a limited period of restriction, but RCTs conducted to date only examine the 384 
effect on symptoms during FODMAP elimination. There is little evidence to support benefit 385 
of a gluten-free diet in IBS. 103 However, as wheat contains fructans, which is a FODMAP, it 386 
incorporates elements of a low FODMAP diet; some patients may, therefore, adapt a low 387 
FODMAP diet to one that instead avoids gluten. 104 There have been numerous RCTs of 388 
probiotics in IBS but, although some trials show positive results, ability to make 389 
recommendations as to which combination, species, or strain is effective is limited due to the 390 
wide variety of products studied, and the conflicting results among individual trials. 105  391 
 392 
First-line Medical Therapies 393 
 Laxatives, antidiarrhoeals, and antispasmodics are all used first-line in IBS. Most 394 
RCTs of these drugs are old, and are hampered by suboptimal methodology and 395 
heterogeneous patient selection, meaning that efficacy according to predominant stool pattern 396 
is uncertain. In addition, efficacy endpoints do not meet current recommendations from the 397 
Food and Drug Administration (FDA) or European Medicines Agency (EMA). Although 398 
osmotic and stimulant laxatives are efficacious in chronic constipation, 106 there is little 399 
evidence for their use in IBS. A placebo-controlled trial of polyethylene glycol in 139 400 
patients with IBS-C demonstrated an increased number of bowel movements, but no 401 
improvement in abdominal pain. 107 Similarly, there are only a few small RCTs of 402 
antidiarrhoeals, such as loperamide. 6 Nevertheless, some patients find laxatives or 403 
antidiarrhoeals useful. Antispasmodic drugs were more efficacious than placebo in a meta-404 
analysis of 26 trials (RR of remaining symptomatic 0.65; 95% CI 0.56 to 0.76), although side 405 
effects were more common (RR 1.60; 95% CI 1.15 to 2.21). 6 In terms of individual drugs, 406 
otilonium, cimetropium, pinaverium, and hyoscine had the most evidence for efficacy; 407 
Ford et al.  Page 18 of 54 
 
availability is an issue in some countries. A 4-week RCT of pinaverium, recruiting 427 408 
Chinese patients with IBS-D, and which used FDA-recommended endpoints, demonstrated a 409 
significant benefit of the drug over placebo for both abdominal pain and diarrhoea, 108 410 
suggesting antispasmodics may be efficacious in IBS-D. Peppermint oil also appeared 411 
superior to placebo in a meta-analysis of seven RCTs (RR of remaining symptomatic 0.54; 412 
95% CI 0.39 to 0.76), 6 although a subsequent placebo-controlled trial of small intestinal or 413 
ileocolonic-release formulations did not demonstrate efficacy for either FDA or EMA-414 
recommended endpoints. 109 415 
 416 
Second-line Medical Therapies 417 
 Given the accepted role of the gut-brain axis in IBS, the use of antidepressant drugs 418 
and CNS targeted medications, or central neuromodulators, as a potential therapy is logical. 419 
There is some evidence for efficacy of TCAs; a meta-analysis of 12 RCTs reported a RR of 420 
remaining symptomatic of 0.65 (95% CI 0.55 to 0.77) compared with placebo, but trial 421 
quality was low and in most RCTs patients were not recruited according to predominant stool 422 
pattern. 110 Adverse events were more common (RR 1.56; 95% CI 1.23 to 1.98). TCAs have 423 
neuromodulatory properties and also slow gastrointestinal transit, 111 so may be best for 424 
patients with predominant pain and/or diarrhoea. Evidence for efficacy of selective serotonin 425 
reuptake inhibitors (SSRIs) in the same meta-analysis was less convincing. 110 A 12-week 426 
placebo-controlled trial of pregabalin in 85 patients failed to demonstrate adequate relief of 427 
symptoms, but there were significant improvements in global symptoms, pain, diarrhoea, and 428 
bloating. 112 All other second-line therapies are licensed and are used based on predominant 429 
stool pattern. 430 
 5-HT4 receptor agonists accelerate gastrointestinal transit. Tegaserod was more 431 
efficacious than placebo in IBS-C, 113 but was withdrawn due to a small excess number of 432 
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cerebrovascular and cardiovascular ischaemic events. It was reintroduced in the USA in 2018 433 
for female patients <65 years without existing cardiovascular disease. Prucalopride, another 434 
5-HT4 agonist, was superior to placebo in chronic constipation; 
106 there are no RCTs in IBS-435 
C. Intestinal secretagogues, such as lubiprostone, linaclotide, plecanatide, and tenapanor act 436 
on ion channels in enterocytes, leading to water efflux, thereby accelerating gastrointestinal 437 
transit and improving stool consistency. Placebo-controlled trials have demonstrated efficacy 438 
of these drugs in IBS-C; 114-117 there have been no head-to-head trials. A network meta-439 
analysis of 15 RCTs demonstrated similar efficacy for all drugs, but linaclotide was ranked 440 
first for improvements in global symptoms, abdominal pain, and stool frequency; tenapanor 441 
ranked first for improvement in bloating. 118 Diarrhoea was the most common adverse event 442 
with all drugs except lubiprostone, which causes nausea in up to 20% of patients. 118 443 
 Licensed therapies for IBS-D include the 5-HT3 antagonists alosetron and ramosetron, 444 
a peripherally acting mixed opioid receptor agonist/antagonist eluxadoline, and the minimally 445 
absorbed antibiotic rifaximin. 5-HT3 antagonists and eluxadoline slow gastrointestinal transit 446 
and reduce visceral hypersensitivity. 119 5-HT3 antagonists also alter rectal compliance. 
120 447 
Rifaximin has been tested on the basis that alterations in the gastrointestinal microbiota and 448 
SIBO may, in part, be responsible for symptoms in IBS; the exact mechanism of action 449 
remains uncertain. 121 Although all these drugs have demonstrated efficacy over placebo, 450 
113,122-124 again there have been no head-to-head trials. A network meta-analysis of 18 RCTs 451 
demonstrated that 5-HT3 receptor antagonists ranked first for improvement in global 452 
symptoms, abdominal pain, and stool consistency. 125 All drugs, except rifaximin, were more 453 
likely to cause constipation than placebo. A crossover placebo-controlled trial of 454 
ondansetron, another 5-HT3 antagonist, in 120 patients with IBS-D demonstrated significant 455 
improvements in stool consistency and urgency, but not pain; 126 a large RCT is ongoing. 127 456 
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 Figure 5 outlines the spectrum of medications available for pain, constipation, and 457 
diarrhoea in IBS, as well as drugs in development. Overall, there is a plethora of choices for 458 
diarrhoea or constipation, but still an unmet clinical need for relief of pain. 459 
 460 
Psychological Therapies 461 
 Similar to central neuromodulators, psychological therapies may exert not only 462 
central effects on mood, but also peripheral effects on pain perception, visceral 463 
hypersensitivity, and gastrointestinal motility. 128,129 A meta-analysis of 36 RCTs 464 
demonstrated that cognitive behavioural therapy (CBT), gut-directed hypnotherapy, 465 
relaxation therapy, multi-component psychological therapy, and dynamic psychotherapy were 466 
all more effective than a control intervention. 110 Some have evidence for efficacy out to 12 467 
months of follow-up. 130 These may be intensive, in terms of hours of therapist contact, but 468 
subsequent RCTs demonstrate that minimal contact CBT, CBT via the telephone, and group 469 
gut-directed hypnotherapy are also effective, even for patients whose symptoms are 470 
refractory to medical therapy. 131-133 Whether earlier intervention with psychological 471 
therapies can change the natural history of IBS, or whether augmentative therapy with a 472 
psychological therapy and a central neuromodulator has additive benefit, is unclear.  473 
 474 
FUTURE DIRECTIONS AND CONTROVERSIES 475 
 Reasons for the difference in prevalence of IBS across different countries, remain 476 
uncertain, and prevalence data from certain regions are lacking. Our understanding of the 477 
epidemiology is likely to increase as the Rome Foundation global cross-sectional survey 478 
database of 73,076 participants is mined further. 15 Despite considerable efforts, a biomarker 479 
for IBS remains elusive. A validation study of antibodies to bacterial toxins and host cell 480 
adhesion proteins performed only modestly in distinguishing IBS from health. 134 A case-481 
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control study reported distinct faecal and urinary metabolomic profiles in those with IBS, 135 482 
which might allow the development of microbe-based treatments. The efficacy of probiotics 483 
and faecal microbiota transplantation is inconsistent, 105,136 although a RCT of faecal 484 
microbiota transplantation using a single, healthy, well-characterised donor demonstrated 485 
efficacy. 137 However, more than 50% of patients in this trial continued to have moderate to 486 
severe symptoms. With the discovery of actionable biomarkers to identify the mechanisms 487 
underlying symptoms the hope is that, in the future, IBS therapy will move away from drugs 488 
targeting the predominant symptom, or symptoms, towards one where patients are stratified 489 
based on underlying pathophysiology, using these biomarkers, in order to facilitate 490 
individualised treatment. 138  491 
 Other pharmacological therapies are in development (Figure 5). Drugs that reduce 492 
uptake of sodium ions from the lumen, via transporters expressed in the intestine, result in 493 
water retention in the lumen and looser stools. These include mizagliflozin, a sodium-glucose 494 
cotransporter-1 inhibitor, and DRAinh-A250, an inhibitor of the solute carrier 26A3. In a 495 
phase 2 placebo-controlled trial of mizagliflozin in patients with chronic constipation, 496 
response rates were significantly higher with 5mg and 10mg doses, and the medication 497 
appeared safe, 139 albeit after only 1 week of treatment. When administered intraluminally, 498 
DRAinh-A250 blocked fluid absorption in mouse colonic loops and reversed loperamide-499 
induced constipation; 140 there are no human studies to date.  500 
Bile acids are physiological laxatives, and are implicated in the pathophysiology of 501 
IBS. 48 Inhibition of the ileal bile acid transporter by elobixibat accelerated colonic transit in 502 
patients with constipation, 141 and a trial in Japan demonstrated that a 10mg dose was 503 
efficacious in patients with constipation, including IBS-C. 142 Although the drug is licensed in 504 
Japan, adverse events occurred in 30% of patients, particularly diarrhoea and abdominal pain, 505 
and this was only a 2-week trial.  506 
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Novel analgesic approaches include further refinements of existing secretagogues. 507 
Cyclic GMP (cGMP) production in enterocytes is stimulated by some of these drugs, such as 508 
linaclotide. When transported into the extracellular space at the basolateral membrane, 143 509 
cGMP leads to decreased conduction of submucosal afferent nociceptive neurons, attenuating 510 
visceral pain. 144 A preliminary RCT of targeted colonic delivery of linaclotide in patients 511 
with IBS-C demonstrated pain relief, without effects on constipation, 145 suggesting that 512 
cGMP release from enterocytes reduces the function of peripheral visceral afferents.  513 
When conventional opioids bind to µ-opioid receptors, they induce analgesia through 514 
activation of G protein-mediated pathways, but they also activate β-arrestin, which inhibits 515 
gastrointestinal motility and depresses central functions, such as cognition and respiration. 516 
New biased µ-opioid receptor ligands activate the G protein pathway exclusively, leading to 517 
analgesia with reduced gastrointestinal dysfunction. 146 Oliceridine is a biased µ-opioid 518 
receptor ligand with comparable analgesic effects to morphine although there are, as yet, no 519 
human studies in visceral pain. 147 The cannabinoid type-2 receptor agonist, olorinab, has the 520 
potential to alter immune function, as well as sensation, given expression of cannabinoid 521 
type-2 receptors in the brain, peripheral nervous system, and gastrointestinal tract. In an 522 
open-label trial in patients with quiescent Crohn’s disease, it reduced abdominal pain and 523 
improved bowel movements. 148 Clinical trials are being conducted in IBS. 149 The histamine-524 
1 receptor antagonist ebastine appears to attenuate visceral hypersensitivity in vitro 
150 and, in 525 
a RCT of 45 patients, led to significant improvements in both global symptoms and 526 
abdominal pain compared with placebo; 150 a larger trial is in progress. 151 527 
In summary, the greater understanding of pathophysiological mechanisms in IBS has 528 
ushered in the development of novel treatment strategies to manage patients, particularly the 529 
abdominal pain component of IBS, for which central neuromodulators or psychological 530 
therapies are currently the main approaches. The diverse molecular mechanisms to which 531 
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drugs in development are targeted augurs for substantial impact in the management of IBS in 532 
the foreseeable future. Nevertheless, a strong doctor-patient relationship with attention to the 533 
clinical history, an appreciation of the impact of symptoms on the patient’s life, together with 534 
an explanation of the condition and its natural history, and shared decision-making, remain 535 
key to effective management. 536 
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FIGURE LEGENDS. 976 
Figure 1. Global Prevalence of Irritable Bowel Syndrome According to the Rome III 977 
Criteria*. 978 
*Note, the prevalence data reported here are taken from studies using the Rome III 979 
criteria for IBS, summarised in references 4, 13, and 15.  980 
Figure 2. Factors Affecting Symptom Severity in Irritable Bowel Syndrome. 981 
Figure 3. Pathophysiological Mechanisms Involved in Irritable Bowel Syndrome.  982 
*Genome-wide association studies have demonstrated associations with variants of 983 
chromosome 9 (reference 56), and mutations in the sucrase-isomaltase gene (references 984 
37 and 38), and studies have shown approximately 2% of IBS patients carry mutations 985 
in SCN5A (reference 57), which alters the function of the voltage-gated 986 
mechanosensitive Na+ channel Nav1.5. 987 
†See references 17 to 20. 988 
±Gastrointestinal symptoms include abdominal pain, abnormal stool form and/or 989 
frequency, and bloating (reference 5); non-gastrointestinal symptoms include back pain, 990 
gynaecological and bladder symptoms, headache, and fatigue (reference 60).  991 
Figure 4. Suggested Diagnostic Algorithm for Patients with Suspected Irritable Bowel 992 
Syndrome. 993 
*Abdominal pain, related to defaecation, associated with change in stool form or stool 994 
frequency (reference 5). 995 
†Full blood count and C-reactive protein/erythrocyte sedimentation rate 996 
±See Table 2. 997 
§Including family history of inflammatory bowel disease, coeliac disease, or colorectal 998 
cancer, or features suggestive of microscopic colitis (female, age ≥50 years; co-existent 999 
autoimmune disease; proton pump inhibitor or non-steroidal anti-inflammatory drug 1000 
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use; duration of diarrhoea < 12 months; weight loss; or nocturnal diarrhoea (references 1001 
77 and 78)). 1002 
‡Consider measuring SeHCAT retention, serum 7α-hydroxy-4-cholesten-3-one, serum 1003 
fibroblast growth factor-19, or 48-hour faecal bile acid excretion, where available, or a 1004 
trial of a bile acid sequestrant, to exclude bile acid diarrhoea.  1005 
**If the initial faecal calprotectin level is within the abnormal range the suspicion for 1006 
inflammatory bowel disease is high, proceed to colonoscopy (reference 74); if the initial 1007 
faecal calprotectin level is indeterminate according to local laboratory values, repeat the 1008 
test off non-steroidal anti-inflammatory drugs and refer for colonoscopy if the repeat 1009 
test remains indeterminate or is within the abnormal range.  1010 
††If features suggestive of a defaecatory disorder, including obstructive symptoms (such 1011 
as a feeling of incomplete evacuation or the need to digitate during defaecation) or 1012 
paradoxical anal contraction on straining during digital rectal examination, are present 1013 
consider anorectal manometry with balloon expulsion testing.  1014 
Figure 5. Current and Emerging Treatment Options for Irritable Bowel Syndrome. 1015 
  1016 
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Table 1. The Rome IV Criteria for Irritable Bowel Syndrome*. 1017 
Rome IV IBS Diagnostic Criteria 
1. Recurrent abdominal pain, on average, at least 1 day per week in the last 3 months and associated with two 
or more or the following: 
a. Related to defaecation; 
b. Associated with a change in frequency of stool; 
c. Associated with a change in stool form. 
AND 
2. Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis 
IBS-C IBS-D IBS-M IBS-U 
≥25% of bowel 
movements of Bristol 
stool form types 1 or 2, 
and <25% of Bristol 
stool form types 6 or 7. 
≥25% of bowel 
movements of Bristol 
stool form types 6 or 7, 
and <25% of Bristol 
stool form types 1 or 2. 
≥25% of bowel 
movements of Bristol 
stool form types 1 or 2, 
and ≥25% of bowel 
movements of Bristol 
stool form types 6 or 7. 
Patients who meet 
criteria for IBS, but who 
do not fall into one of the 
other three subgroups 
according to Bristol stool 
form type. 
*Adapted from reference 5. 1018 
  1019 
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Table 2. Lower Gastrointestinal Alarm Symptoms and Signs (Based on the UK’s NICE 1020 
Guidance*). 1021 
Definite Referral Criteria 
 Aged ≥40 years with unexplained weight loss and abdominal pain. 
 Aged ≥50 years with unexplained rectal bleeding. 
 Aged ≥60 years with change in bowel habit, a positive faecal occult blood test, or iron deficiency 
anaemia. 
*Adapted from reference 71. Regardless of age, adults with unexplained rectal bleeding or 1022 
iron-deficiency anaemia (especially if accompanied by abdominal pain, change in bowel 1023 
habit, or weight loss), or an abdominal or rectal mass, need investigation to exclude other 1024 
gastrointestinal disorders, including cancer. 1025 
  1026 
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Adverse Events Limitations of Data 
Diet, lifestyle, and 
probiotics 
Soluble fibre 
(e.g. ispaghula 20 -
30g/day) 
No specific IBS 
subgroup 
recruited 
Effective Moderate Total adverse events no more 
common with soluble fibre in 
three RCTs 
Only one RCT at low risk of bias; only a 
small number of patients in existing RCTs 





Very low Total adverse events rarely 
reported 
All RCTs at high risk of bias; heterogeneity 
between study designs; imprecision in 
estimate of effect; impact of FODMAP 
reintroduction not studied within the design 





Very low Total adverse events not 
reported 
Only two RCTs, which were at high risk of 
bias; inconsistent effects on symptoms 





Very low Total adverse events no more 
common with probiotics in a 
meta-analysis of 36 RCTs 
Heterogeneity between studies; possible 
publication bias; only a small number of 
RCTs assessing each individual probiotic, 
meaning that it is difficult to know which 
species or strain is effective 
First-line therapies 
Peppermint oil 
(200mg three times 
daily) 
No specific IBS 
subgroup 
recruited 
Effective Low Total adverse events no more 
common with peppermint oil 
in a meta-analysis of six 
RCTs 
Only two RCTs at low risk of bias; 
heterogeneity between studies; trials used 
very specific formulations so data cannot be 
extrapolated to other available products; 
heartburn may be an issue 
Laxatives 
(e.g. polyethylene 
glycol 13.8g once 





Low Rates of abdominal pain 
numerically higher with 
polyethylene glycol in one 
RCT 
Only two RCTs; both RCTs unclear risk of 
bias; effect on abdominal pain unclear 
Antidiarrhoeals (e.g. 







Very low Total adverse events no more 
common with antidiarrhoeals 
in two RCTs 
Only two RCTs; both RCTs unclear risk of 
bias; not all patients met criteria for IBS; no 
significant effect on IBS symptoms when 
data pooled; constipation may be an issue 




three times daily, 
hyoscine 10-20 mg 
three times daily, 
otilonium20-40mg 
three times daily, or 
pinaverium 50mg 
three times daily) 
No specific IBS 
subgroup 
selected, other 
than one RCT 




Very low Total adverse events 
significantly more common 
with antispasmodics in a 
meta-analysis of 26 RCTs, 
particularly dry mouth, 
dizziness, and blurred vision 
Only two RCTs at low risk of bias; 
heterogeneity between studies; possible 
publication bias; only a small number of 
RCTs assessing each individual 
antispasmodic 
Second-line therapies 
5-HT4 agonists (e.g. 
tegaserod 6mg twice 
daily) 
IBS-C Effective High Diarrhoea significantly more 
common with tegaserod in a 
meta-analysis of six RCTs 
Concerns regarding small excess of 
cardiovascular and cerebrovascular events 
led to withdrawal of tegaserod, reintroduced 
in 2018 but only for specific patients; no 
RCTs of prucalopride 
Linaclotide (290mcg 
once daily) 
IBS-C Effective High Diarrhoea significantly more 
common with linaclotide in a 




1mg twice daily, 
ramosetron 2.5-5mcg 
once daily, or 
ondansetron 4mg once 
daily and titrated) 
IBS-D and IBS-
M 
Effective High Constipation significantly 
more common with alosetron 
in a meta-analysis of three 
RCTs 
All RCTs of ramosetron conducted in Japan; 
serious adverse events with alosetron 
included ischaemic colitis and severe 
constipation leading to restricted use; 
ramosetron is safer, although constipation is 
still more common with active therapy 
TCAs (e.g. 
amitriptyline 10-30mg 
at night or 
desipramine 50mg at 
night) 
No specific IBS 
subgroup 
selected, other 
than one RCT 
in patients with 
IBS-D 
Effective Moderate Total adverse events 
significantly more common 
with TCAs in a meta-analysis 
of six RCTs, particularly dry 
mouth and drowsiness 
Only three RCTs at low risk of bias; 




IBS-C Effective Moderate Nausea significantly more 
common with lubiprostone in 
a meta-analysis of three 
RCTs 




IBS-C Effective Moderate Diarrhoea significantly more 
common with plecanatide in 
a meta-analysis of two RCTs 
Only a modest benefit over placebo in 
published RCTs 




IBS-C Effective Moderate Rates of diarrhoea 
numerically higher with 
tenapanor 
Awaiting publication of all phase 3 trial data 
Eluxadoline (100mg 
twice daily) 
IBS-D Effective Moderate Rates of constipation, 
nausea, and vomiting 
numerically higher with 
eluxadoline in a pooled 
analysis of two RCTs 
Heterogeneity between studies; only a 
modest benefit over placebo in published 
RCTs; no benefit over placebo in terms of 
abdominal pain; serious adverse events 
include acute pancreatitis and sphincter of 
Oddi spasm 
Rifaximin (550mg 
three times daily) 
IBS-D and IBS-
M 
Effective Moderate Total adverse events no more 
common with rifaximin in a 
pooled analysis of three 
RCTs 
Only a modest benefit over placebo in 
published RCTs 
SSRIs (e.g. fluoxetine 
20mg once daily) 
No specific IBS 
subgroup 
selected, other 
than one RCT 




Low Total adverse events no more 
common with SSRIs 
Only one RCT at low risk of bias; 
heterogeneity between studies 
Pregabalin (225mg 
twice daily) 





Low Total adverse events 
numerically higher with 
pregabalin, particularly 
blurred vision, dizziness, and 
altered sensation 
Only one single-centre RCT although global 
symptoms, abdominal pain, diarrhoea, and 
bloating improved significantly 
Psychological 
therapies 
CBT or gut-directed 
hypnotherapy 
No specific IBS 
subgroup 
recruited 
Effective Very low Adverse events not reported 
in individual RCTs, 
precluding their assessment 
in a meta-analysis of 36 
RCTs 
All RCTs at high risk of bias due to the 
nature of the interventions studied; 
heterogeneity between studies; possible 
publication bias; only a small number of 
RCTs assessing each intervention; time 
consuming due to need for therapist contact; 
limited availability in some countries 
*Data adapted from reference 6. 
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†Most drugs should be trialled for 3 months, with their efficacy then reviewed, with the exception of rifaximin, which is a 2-week 
treatment course. A low FODMAP diet should not be maintained long-term; the restriction phase in RCTs to date has been a maximum 
of 3 to 4 weeks.  
